0000000000433364
AUTHOR
Francisco Tinahones
Additional file 1: of Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial
Detailed metabolomic analysis procedure ([51, 52]). (DOCX 15 kb)
Additional file 6: Figure S4. of Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial
Principal component analysis (PCA) to discriminate between the baseline and final states in group 3 (suspected NAFLD reversion cases). Model diagnostics (A = 6, R2X = 0.628, Q2X = 0.235) (DOCX 42 kb)
Additional file 5: Figure S3. of Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial
Principal component analysis (PCA) to discriminate between the baseline and final states in group 2 (suspected cases of NAFLD). Model diagnostics (A = 6, R2X = 0.624, Q2X = 0.179) (DOCX 39 kb)
Additional file 4: Figure S2. of Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial
Principal component analysis (PCA) model to discriminate between the baseline and final states in group 1 (participants not meeting the NAFLD criteria at baseline and at the end of follow-up). Model diagnostics (A = 6, R2X = 0.621, Q2X = 0.160) (DOCX 43 kb)
Additional file 5: Figure S3. of Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial
Principal component analysis (PCA) to discriminate between the baseline and final states in group 2 (suspected cases of NAFLD). Model diagnostics (A = 6, R2X = 0.624, Q2X = 0.179) (DOCX 39 kb)
Additional file 11: Figure S9. of Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial
Volcano plot [−log10 (p-value) vs. log2 (fold-change)] for the comparison between the baseline and final states in group 3 (suspected NAFLD reversion cases). Abbreviations: AA, amino acids; SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids; MUFA, monounsaturated fatty acids; NAE, N-acyl ethanolamines; FFAox, free fatty acid oxidised; AC, acyl carnitines; PC, phosphatidylcholine; LPC, lysophosphatidylcholine; PE, phatidylethanolamine; LPE, lysophosphatidylethanolamine; PI, phatidylinositols; LPI, lysophosphatidylinositols; Cer, ceramides; SM, sphingomyelin; ChoE, cholesteryl esters; Chol, cholesterol; TAG, triacylglycerols; DAG, diacylglycerols, BA, bile acids; CMH, monohexosylce…
Additional file 7: Figure S5. of Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial
Heatmap representing individual metabolomic features obtained from the comparisons between the three baseline states in groups 1, 2 and 3.Heatmapcolor codes for log2 (fold-change) and ANOVA and Tukey’s Honestly Significance Difference post hoc test p-values are indicated at the bottom of the Figure. Darker green and red colors indicate higher drops or elevations of the metabolite levels in every comparison. Grey lines correspond to significant fold-changes of individual metabolites, darker grey colors have been used to highlight higher significances (p
Additional file 3: Figure S1. of Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial
Principal component analysis (PCA) model to discriminate between the three baseline states in groups 1, 2 and 3. Model diagnostics (A = 8, R2X = 0.651, Q2X = 0.264) (DOCX 43 kb)
Seafood Consumption, Omega-3 Fatty Acids Intake, and Life-Time Prevalence of Depression in the PREDIMED-Plus Trial.
Background: The aim of this analysis was to ascertain the type of relationship between fish and seafood consumption, omega-3 polyunsaturated fatty acids (&omega
Additional file 2: of Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial
Estimation of the index of enzyme activities. (DOCX 11 kb)
Additional file 9: Figure S7. of Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial
Volcano plot [−log10 (p-value) vs. log2 (fold-change)] for the comparison between the baseline and final states in group 1 (not meeting the NAFLD criteria at baseline and during the follow-up).Abbreviations: AA, amino acids; SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids; MUFA, monounsaturated fatty acids; NAE, N-acyl ethanolamines; FFAox, free fatty acid oxidised; AC, acyl carnitines; PC, phosphatidylcholine; LPC, lysophosphatidylcholine; PE, phatidylethanolamine; LPE, lysophosphatidylethanolamine; PI, phatidylinositols; LPI, lysophosphatidylinositols; Cer, ceramides; SM, sphingomyelin; ChoE, cholesteryl esters; Chol, cholesterol; TAG, triacylglycerols; DAG, diacylglycerols,…
MOESM1 of Isotemporal substitution of inactive time with physical activity and time in bed: cross-sectional associations with cardiometabolic health in the PREDIMED-Plus study
Additional file 1: Table S1. Associations of total inactive time with adiposity indicators and cardio-metabolic risk factors (with further adjustment for light physical activity, instead of moderate-to-vigorous physical activity). Table S2. Associations of total inactive time with adiposity indicators and cardio-metabolic risk factors (with further adjustment for light physical activity, instead of moderate-to-vigorous physical activity and waist circumference as an indicator of adiposity). Table S3. Prevalence ratio of metabolic syndrome parameters according to tertiles of sedentary time (with further adjustment for light physical activity, instead of moderate-to-vigorous physical activity…
Additional file 3: Figure S1. of Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial
Principal component analysis (PCA) model to discriminate between the three baseline states in groups 1, 2 and 3. Model diagnostics (A = 8, R2X = 0.651, Q2X = 0.264) (DOCX 43 kb)
Additional file 4: Figure S2. of Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial
Principal component analysis (PCA) model to discriminate between the baseline and final states in group 1 (participants not meeting the NAFLD criteria at baseline and at the end of follow-up). Model diagnostics (A = 6, R2X = 0.621, Q2X = 0.160) (DOCX 43 kb)
Additional file 8: Figure S6. of Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial
Heatmap representing individual metabolomic features obtained from all the comparisons made between the final and the baseline states in groups 1, 2 and 3. Heatmapcolor codes for log2 (fold-change) and Student’s t-test p-values are indicated at the bottom of the Figure. Darker green and red colors indicate higher drops or elevations of the metabolite levels in every comparison. Grey lines correspond to significant fold-changes of individual metabolites, darker grey colors have been used to highlight higher significances (p
Additional file 10: Figure S8. of Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial
Volcano plot [−log10 (p-value) vs. log2 (fold-change)] for the comparison between the baseline and final states in group 2 (suspected cases of NAFLD). Abbreviations: AA, amino acids; SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids; MUFA, monounsaturated fatty acids; NAE, N-acyl ethanolamines; FFAox, free fatty acid oxidised; AC, acyl carnitines; PC, phosphatidylcholine; LPC, lysophosphatidylcholine; PE, phatidylethanolamine; LPE, lysophosphatidylethanolamine; PI, phatidylinositols; LPI, lysophosphatidylinositols; Cer, ceramides; SM, sphingomyelin; ChoE, cholesteryl esters; Chol, cholesterol; TAG, triacylglycerols; DAG, diacylglycerols, BA, bile acids; CMH, monohexosylceramides…
Additional file 6: Figure S4. of Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial
Principal component analysis (PCA) to discriminate between the baseline and final states in group 3 (suspected NAFLD reversion cases). Model diagnostics (A = 6, R2X = 0.628, Q2X = 0.235) (DOCX 42 kb)
Additional file 9: Figure S7. of Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial
Volcano plot [−log10 (p-value) vs. log2 (fold-change)] for the comparison between the baseline and final states in group 1 (not meeting the NAFLD criteria at baseline and during the follow-up).Abbreviations: AA, amino acids; SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids; MUFA, monounsaturated fatty acids; NAE, N-acyl ethanolamines; FFAox, free fatty acid oxidised; AC, acyl carnitines; PC, phosphatidylcholine; LPC, lysophosphatidylcholine; PE, phatidylethanolamine; LPE, lysophosphatidylethanolamine; PI, phatidylinositols; LPI, lysophosphatidylinositols; Cer, ceramides; SM, sphingomyelin; ChoE, cholesteryl esters; Chol, cholesterol; TAG, triacylglycerols; DAG, diacylglycerols,…
Additional file 8: Figure S6. of Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial
Heatmap representing individual metabolomic features obtained from all the comparisons made between the final and the baseline states in groups 1, 2 and 3. Heatmapcolor codes for log2 (fold-change) and Student’s t-test p-values are indicated at the bottom of the Figure. Darker green and red colors indicate higher drops or elevations of the metabolite levels in every comparison. Grey lines correspond to significant fold-changes of individual metabolites, darker grey colors have been used to highlight higher significances (p
Additional file 7: Figure S5. of Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial
Heatmap representing individual metabolomic features obtained from the comparisons between the three baseline states in groups 1, 2 and 3.Heatmapcolor codes for log2 (fold-change) and ANOVA and Tukey’s Honestly Significance Difference post hoc test p-values are indicated at the bottom of the Figure. Darker green and red colors indicate higher drops or elevations of the metabolite levels in every comparison. Grey lines correspond to significant fold-changes of individual metabolites, darker grey colors have been used to highlight higher significances (p